دورية أكاديمية
أعرض في EDS

Short term health-related quality of life improvement during opioid agonist treatment.

التفاصيل البيبلوغرافية
العنوان: Short term health-related quality of life improvement during opioid agonist treatment.
المؤلفون: Nosyk B; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada. Electronic address: bnosyk@cfenet.ubc.ca., Bray JW; Department of Economics, University of North Carolina, Greensboro, NC, United States; Research Triangle International, Durham, NC, United States., Wittenberg E; Harvard School of Public Health, Boston, MA, United States., Aden B; Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, NY, United States., Eggman AA; Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, NY, United States., Weiss RD; Harvard Medical School, Boston, MA, United States; McLean Hospital, Belmont, MA, United States., Potter J; Departments of Psychiatry and Anesthesiology (Pain Medicine), Faculty of Medicine, University of Texas Health Science Center, San Antonio, TX, United States., Ang A; UCLA Integrated Substance Abuse Programs, Los Angeles, CA, United States., Hser YI; UCLA Integrated Substance Abuse Programs, Los Angeles, CA, United States., Ling W; UCLA Integrated Substance Abuse Programs, Los Angeles, CA, United States., Schackman BR; Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, NY, United States.
المصدر: Drug and alcohol dependence [Drug Alcohol Depend] 2015 Dec 01; Vol. 157, pp. 121-8. Date of Electronic Publication: 2015 Oct 25.
نوع المنشور: Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: Ireland NLM ID: 7513587 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0046 (Electronic) Linking ISSN: 03768716 NLM ISO Abbreviation: Drug Alcohol Depend Subsets: MEDLINE
أسماء مطبوعة: Publication: Limerick : Elsevier
Original Publication: Lausanne, Elsevier Sequoia.
مواضيع طبية MeSH: Health Status*, Opiate Substitution Treatment/*psychology , Opioid-Related Disorders/*psychology , Quality of Life/*psychology, Adult ; Analgesics, Opioid/adverse effects ; Analgesics, Opioid/therapeutic use ; Buprenorphine, Naloxone Drug Combination/therapeutic use ; Cost-Benefit Analysis ; Female ; Heroin/adverse effects ; Humans ; Male ; Methadone/therapeutic use ; Middle Aged ; Opiate Substitution Treatment/methods ; Opioid-Related Disorders/drug therapy ; Randomized Controlled Trials as Topic
مستخلص: Background: Opioid dependence is associated with high levels of morbidity, yet sparse data exists regarding the health-related quality of life (HRQoL) of individuals with opioid dependence, particularly following treatment initiation. To inform cost-effectiveness analyses of treatment modalities, this study investigates short-term changes in HRQoL following enrollment into opioid agonist treatment (OAT), across treatment modalities and patient subgroups.
Methods: Data was analyzed from the Starting Treatment with Agonist Replacement Therapies (START) and Prescription Opioid Addiction Treatment Studies (POATS) randomized controlled trials. Participants included individuals dependent on prescription opioids (POs) or heroin, receiving limited-term or time-unlimited treatment. PO- or heroin-users in START received buprenorphine/naloxone (BUP/NX) or methadone (MET) over 24 weeks. PO-users in POATS received psychosocial care and short-term (4-week) taper with BUP/NX, with non-responders offered subsequent extended (12-week) stabilization and taper. HRQoL was assessed using the short-form SF-6D while in and out of OAT, with distinction between MMT and BUP/NX in START. Linear mixed effects regression models were fitted to determine the independent effects of OAT on HRQoL and characterize HRQoL trajectories.
Results: Treatment had a similar immediate and modest positive association with HRQoL in each patient subgroup. The association of OAT on HRQoL was statistically significant in each model, with effect sizes between 0.039 (heroin-users receiving BUP/NX) and 0.071 (PO-users receiving MET). After initial improvement, HRQoL decreased slightly, or increased at a diminished rate.
Conclusions: OAT, whether delivered in time-limited or unlimited form, using BUP/NX or MET, is associated with modest immediate HRQoL improvements, with diminishing benefits thereafter.
(Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.)
References: Eur Addict Res. 2008;14(2):99-105. (PMID: 18334820)
Subst Use Misuse. 2008;43(5):612-32. (PMID: 18393080)
Cochrane Database Syst Rev. 2008;(2):CD002207. (PMID: 18425880)
JAMA. 2008 Nov 19;300(19):2303-5. (PMID: 19017918)
J Subst Abuse Treat. 2009 Dec;37(4):426-30. (PMID: 19553061)
Value Health. 2010 Jun-Jul;13(4):487-94. (PMID: 20230549)
Drug Alcohol Depend. 2010 Dec 1;112(3):209-15. (PMID: 20728288)
Addiction. 2011 Jan;106(1):32-51. (PMID: 21054613)
J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S39-45. (PMID: 21317593)
Health Aff (Millwood). 2011 Aug;30(8):1411-9. (PMID: 21821558)
Med Care. 2000 Sep;38(9):902-10. (PMID: 10982112)
Clin Infect Dis. 2014 Nov 15;59(10):1411-9. (PMID: 25114031)
J Health Econ. 2002 Mar;21(2):271-92. (PMID: 11939242)
Addiction. 2003 May;98(5):693-702. (PMID: 12751987)
Cochrane Database Syst Rev. 2003;(3):CD002208. (PMID: 12917925)
Med Care. 2004 Sep;42(9):851-9. (PMID: 15319610)
Health Econ. 2004 Sep;13(9):873-84. (PMID: 15362179)
Subst Use Misuse. 2004 Jul;39(9):1353-68. (PMID: 15462234)
Med Care. 1992 Jun;30(6):473-83. (PMID: 1593914)
JAMA. 1998 Dec 9;280(22):1936-43. (PMID: 9851480)
Med Care. 2005 Jun;43(6):574-85. (PMID: 15908852)
J Subst Abuse Treat. 2005 Jun;28(4):321-9. (PMID: 15925266)
Qual Life Res. 2005 Aug;14(6):1523-32. (PMID: 16110932)
Eur Addict Res. 2006;12(2):74-82. (PMID: 16543742)
J Gen Intern Med. 2007 Apr;22(4):527-30. (PMID: 17372805)
Am J Drug Alcohol Abuse. 2007;33(5):631-42. (PMID: 17891656)
Med Decis Making. 2011 Nov-Dec;31(6):790-9. (PMID: 22067429)
Arch Gen Psychiatry. 2011 Dec;68(12):1238-46. (PMID: 22065255)
Am J Drug Alcohol Abuse. 2012 May;38(3):213-9. (PMID: 22352836)
J Gen Intern Med. 2012 Jun;27(6):669-76. (PMID: 22215271)
J Stud Alcohol Drugs. 2013 Jul;74(4):605-13. (PMID: 23739025)
Health Aff (Millwood). 2013 Aug;32(8):1462-9. (PMID: 23918492)
JAMA. 2013 Oct 9;310(14):1433-4. (PMID: 24104358)
Drug Alcohol Depend. 2014 Oct 1;143:149-57. (PMID: 25110333)
JAMA. 2000 Oct 4;284(13):1689-95. (PMID: 11015800)
Drug Alcohol Depend. 2011 Nov 1;118(2-3):259-64. (PMID: 21546173)
MMWR Morb Mortal Wkly Rep. 2011 Nov 4;60(43):1487-92. (PMID: 22048730)
معلومات مُعتمدة: U10 DA015831 United States DA NIDA NIH HHS; K24-DA022288 United States DA NIDA NIH HHS; U10-DA15831 United States DA NIDA NIH HHS; K24 DA022288 United States DA NIDA NIH HHS; R01 DA031727 United States DA NIDA NIH HHS; R01-DA033424 United States DA NIDA NIH HHS; R01 DA033424 United States DA NIDA NIH HHS; R01-DA031727 United States DA NIDA NIH HHS
فهرسة مساهمة: Keywords: Buprenorphine/naloxone; HRQoL; Health related quality of life; Health utility; Methadone; Opioid agonist treatment; Opioid use disorder; Suboxone
المشرفين على المادة: 0 (Analgesics, Opioid)
0 (Buprenorphine, Naloxone Drug Combination)
70D95007SX (Heroin)
UC6VBE7V1Z (Methadone)
تواريخ الأحداث: Date Created: 20151030 Date Completed: 20160706 Latest Revision: 20220331
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC4778423
DOI: 10.1016/j.drugalcdep.2015.10.009
PMID: 26511766
قاعدة البيانات: MEDLINE
الوصف
تدمد:1879-0046
DOI:10.1016/j.drugalcdep.2015.10.009